Correction to: Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study
Crossref DOI link: https://doi.org/10.1007/s12325-021-01813-8
Published Online: 2021-07-19
Published Print: 2021-08
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Nakamura, Ichiro
Maegawa, Hiroshi
Tobe, Kazuyuki
Uno, Satoshi
Text and Data Mining valid from 2021-07-19
Version of Record valid from 2021-07-19
Article History
First Online: 19 July 2021